**Nov. 3, 2011: Bass Introduced a Generic Rx Bill**

On July 13, 2011, Sen. Brown introduced the Affordable Medicines Utilization Act of 2011 (S 1356), a bill designed to encourage states to purchase generic drugs instead of brand name prescriptions for their Medicaid programs.

On November 3, 2011, Rep. Bass introduced a companion bill (HR 3342) in the House of Representatives. According to Rep. Bass, the bill “will allow states to keep 50 percent of the Federal Medical Assistance Percentage (FMAP) savings directly associated with an increase in generic drug substitution.

Unlike the Senate version of the bill, Bass’ bill also created a grant program for states with higher generic substitution rates of 92 to implement other ways to achieve further savings in Medicaid. [Library of Congress, accessed [9/6/2012](http://hdl.loc.gov/loc.uscongress/legislation.112hr3342); bass.house.gov, accessed [9/6/2012](http://bass.house.gov/index.php?option=com_content&task=view&id=3246&Itemid=400158)]

**Dec. 1, 2011: Bass Took $1,000 from the Largest Pharmaceutical Manufacturer**

One month after the bill was introduced, Teva Pharmaceuticals, the largest manufacturer of generic drugs, donated $1,000 to Rep. Bass. ***This is the first time Teva Pharmaceuticals had given to Rep. Bass***. [fec.gov, accessed [9/05/2012](http://herndon1.sdrdc.com/cgi-bin/fecimg/?12970371902)]

**Teva Lobbied on Bass’ Rx Drug Bill, Spent $32 Million Pushing Legislative Agenda**

TWO BUCKETS

Lobbying Report mentioned House Bill

Lobbying Report mentioned Senate Bill

Explain the two buckets and what you found

* Looper Consulting LLC Second Quarter Filing [7/19/2011](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=a72c0bd0-ce43-4bc1-bb23-36de51b50afa)
* Integrated Solutions Group Second Quarter Filing [7/19/2011](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=9cc0ba14-7c93-492b-92c4-b739eb9591ed)
* Looper Consulting LLC Third Quarter Filing [10/07/2011](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=f9afdabd-a168-43fb-b6dc-c606725e3d1c)
* Integrated Solutions Group Third Quarter Filing [10/20/2011](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=1e6d59a2-de9d-4b15-baf6-)
* Integrated Solutions Group Third Quarter Filing [10/20/2011](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=12cf138d-7988-47b2-bb83-1b1dd2b07b36)
* Teva Pharmaceuticals USA Third Quarter Filing [10/20/2011](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=c2050354-bb54-4f09-af25-e6e63a4e1265)
* Integrated Solutions Group Fourth Quarter Filing [1/17/2012](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=fecf47f9-ba13-4d19-a192-e0f7f1ed7973)
* Looper Consulting LLC Fourth Quarter Filing [1/18/2012](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=5102d9a3-0325-42d2-86b3-526eefe768a4)
* Teva Pharmaceuticals Fourth Quarter Filing [1/20/2012](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=8f50e718-fb2d-452b-8f9a-90cd6bc0ac44)
* Integrated Solutions Group First Quarter [4/18/2012](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=7c2def79-f727-462a-8606-6a5386dfdc76)
* Teva Pharmaceuticals First Quarter [4/20/2012](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=9a06cff6-5bfa-4970-8a12-8832a326042d)
* Teva Pharmaceuticals Second Quarter [7/19/2012](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=e788d65c-d150-4cc0-990a-13dfe394a04a)
* Integrated Solutions Group Second Quarter [7/20/2012](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=39deda35-f8a7-4623-81e7-dbe662650fae)

Since 2001, the company has spent $32,235,000 pushing its legislative agenda in Congress.

[Teva Pharmaceuticals’ Website, accessed [9/05/2012](http://www.tevausa.com/default.aspx?pageid=3402); Senate Office of Public Records, accessed [9/5/2012](http://soprweb.senate.gov)]

**January 2012: Bass’s “Senior Policy Advisor” Leaves Congress to Lobby for Teva on Bass’ Bill**

From XXX to XXX, Grant Erdel worked from Rep. Bass. While Erdel was promoted several times, by the time he finished working for Rep. Bass’s Senior Policy Advisor, Erdel earned XXXXXXXX annually.

ON DATE, Grant Erdel, Bass’s former “Senior Policy Advisor.” left Bass’s office to become the Director of Federal Affairs for Teva. [Linkedin.com, [accessed 9/05/2012](http://www.linkedin.com/pub/grant-erdel/6/3b0/39b)]

According to lobbying disclosure reports, he lobbied on XXXXX from XXXX to XXXX.

DID HE ACTUALLY LOBBYING ON THE BILL???? BUCKET #3 – MENTIONED ON XXX Reprot about the bill. Senate verison? House version?

**Bass Receives Additional $5,000 from Teva Two Months After Erdel Becomes Director of Federal Affairs**

On March 7th, 2012, Teva donated an additional $5,000 to Rep. Bass’s reelection campaign. [fec.gov, [accessed 9/05/2012](http://herndon1.sdrdc.com/cgi-bin/fecimg/?12970879554)]

**Bass is Among the Top Recipients of Teva’s PAC Dollars**

During the 2012 election cycle, Rep. Bass took $6,000 from Teva Pharmaceutical’s political action committee. Only two more members of Congress took more.

EMPLOYEES??????

|  |  |  |
| --- | --- | --- |
| **Donor** | **Amount** | **Date** |
| Teva Pharmaceuticals USA, Inc Political Action Committee | [$1,000](http://herndon1.sdrdc.com/cgi-bin/fecimg/?12970371902)  | 12/1/2011 |
| Teva Pharmaceuticals USA, Inc Political Action Committee | [$4,000](http://herndon1.sdrdc.com/cgi-bin/fecimg/?12970879554)  | 3/7/2012 |
| Teva Pharmaceuticals USA, Inc Political Action Committee | [$1,000](http://herndon1.sdrdc.com/cgi-bin/fecimg/?12970879554)  | 3/7/2012 |
| **Total** | **$6,000**  |  |

[CQ Moneyline, accessed 9/6/12; opensecrets.org, [9/06/2012](http://www.opensecrets.org/pacs/pacgot.php?cycle=2012&cmte=C00434811)]

**~~Bass Received $8,000 from Other Companies that Lobbied on HR 3342~~ NEW HEADERs**

**NO LOBBYING CITATION???**

**IS THIS TOTAL FROM PACS?**

**HOW ABOUT EMPLOYEES?**

|  |  |  |
| --- | --- | --- |
| **PAC** | **Amount** | **Date** |
| Generic Pharmaceutical Association political Action Committee | [$2,500](http://herndon1.sdrdc.com/cgi-bin/fecimg/?12970912699)  | 3/7/2012 |
| Walgreen PAC | [$2,000](http://herndon1.sdrdc.com/cgi-bin/fecimg/?12951282202)  | 2/23/2012 |
| Food Marketing Institute Political Action Committee | [$2,500](http://herndon1.sdrdc.com/cgi-bin/fecimg/?11932011279)  | 6/22/2011 |
| Food Marketing Institute Political Action Committee | [$1,000](http://herndon1.sdrdc.com/cgi-bin/fecimg/?11931493052)  | 4/15/2011 |
| **Total** | **$8,000**  |  |

**Pharmaceutical Industry has Donated $96,800 to Bass since 2002**

In 2012, Rep. Bass received over $49,000 from the pharmaceutical industry. That figure is nearly twice what he raised from pharmaceuticals in 2010 and close to five times what he raised from the industry in 2006.

|  |  |
| --- | --- |
| **Cycle**  | **Total Contributions from Pharmaceutical Industry** |
| 2012 | [$49,250](http://www.opensecrets.org/politicians/industries.php?cycle=2012&cid=N00000423&type=I)  |
| 2010 | [$26,350](http://www.opensecrets.org/politicians/industries.php?cycle=2010&type=I&cid=N00000423&newMem=N&recs=20)  |
| 2006 | [$11,500](http://www.opensecrets.org/politicians/industries.php?cycle=2006&type=I&cid=N00000423&newMem=N&recs=20)  |
| 2004 | [$5,700](http://www.opensecrets.org/politicians/industries.php?cycle=2004&type=I&cid=N00000423&newMem=N&recs=20)  |
| 2002 | [$4,000](http://www.opensecrets.org/politicians/industries.php?cycle=2002&type=I&cid=N00000423&newMem=N&recs=20)  |
| 2000 | [Not Listed](http://www.opensecrets.org/politicians/industries.php?cycle=2000&type=I&cid=N00000423&newMem=N&recs=20) |
| 1998 | [Not Listed](http://www.opensecrets.org/politicians/industries.php?cycle=1998&type=I&cid=N00000423&newMem=N&recs=20) |
| **Total** | **$96,800**  |

**House Ethics Header**

In 2007, Congress passed the Honest leadership and blah blah blah

The bill was meant to slow rapidly revolving door between the Hill and K street.

People said, “wow that is awesome”

What the law didn’t do was require people earning under XXXXXXX

~~Erdel was compensated as a “Senior Policy Advisor” and paid less than the cutoff for senior staff under House ethics rules. On the lobbying disclosure forms filed for Teva, Erdel is listed as Rep. Bass’s former legislative director. Disbursements reported from Rep. Bass’s office do not list a legislative director for 2011 4~~~~th~~ ~~quarter. [Congressional Research Service,~~ [~~5/12/2010~~](http://www.fas.org/sgp/crs/misc/97-875.pdf)~~; House Disbursements 2011 4~~~~th~~ ~~Quarter,~~ [~~accessed 9/05/2012~~](http://disbursements.house.gov/2011q4/2011q4_singlevolume.pdf)~~]~~

~~House Ethics rules prohibit senior staff from lobbying their former offices for two years. Erdel lobbied on the Senate bill instead of the House bill. The Senate bill, S. 1356, is almost identical to the House bill. The House bill contains an additional section that would provide payments to states to help them reduce the cost of Medicaid. Both bills contain the same language providing incentives to states to use more generic drugs in Medicaid. Thomas.loc.gov,~~ [~~accessed 9/06/2012~~](http://thomas.loc.gov/cgi-bin/query/z?c112:S.1356.IS:/)~~; Thomas.loc.gov,~~ [~~accessed 9/06/2012~~](http://thomas.loc.gov/cgi-bin/bdquery/z?d112:H.R.3342:@@@D&amp;summ2=m&amp;)~~; Secretary of the Senate,~~ [~~accessed 9/05/2012~~](http://soprweb.senate.gov/index.cfm?event=getFilingDetails&filingID=9a06cff6-5bfa-4970-8a12-8832a326042d)~~; House Ethics Manual 110~~~~th~~ ~~Congress,~~ [~~accessed 9/05/2012~~](http://ethics.house.gov/sites/ethics.house.gov/files/documents/2008_House_Ethics_Manual.pdf)~~]~~